Comparison of the use of enoxaparin versus unfractionated heparin in patients undergoing lower extremity revascularization

Vascular and Endovascular Surgery

Volumn 36, Issue 3, 2002, Pages 199-205

  Paramo, Juan Carlos ^a   Sendzischew, Harry ^a   Sivina, Manuel ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN DERIVATIVE; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG EFFICACY; FEMALE; HEPARINIZATION; HOSPITAL COST; HUMAN; LEG REVASCULARIZATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; SAPHENOUS VEIN; THROMBOSIS;

EID: 0036588655     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/153857440203600307     Document Type: Article

References (32)

1. Kraiss LW, Johansen K: Pharmacologic intervention to prevent graft failure. Surg Clin North Am 75:761-772, 1995.
2. Swedenborg J, Nydahl S, Egberg N: Low molecular mass heparin instead of unfractionated heparin during infrainguinal bypass surgery. Eur J Vasc: Endovasc Surg 11:59-64, 1996.
3. Edmondson RA, Cohen AT, Das SK, et al: Low molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 344: 914-918, 1994.
4. McMillan WD, McCarthy WJ, Lin SJ, et al: Perioperative low molecular weight heparin for infrageniculate bypass. J Vasc Surg 25:796-802, 1997.
5. Hirsch J, Levine MN: Low molecular weight heparin. Blood 79:1-17, 1992.
6. Samama MM, Bara L, Gerotziafas GT: Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 24:105-117, 1994.
7. Jackson MR, Clagett GP: Antithrombotic therapy in peripheral arterial occlusive disease. Chest 114:666S-682S, 1998.
8. Rutherford RB, Jones DN, Bergentz S-E, et al: The efficacy of dextran 40 in preventing early postoperative thrombosis following difficult lower extremity bypass. J Vasc Surg 1:765-773, 1984.
9. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet treatment: Part II. Maintenance of vascular graft or arterial patency. Br Med J 308:159-168, 1994.
10. McCollum C, Alexander C, Kenchington G, et al: Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. J Vasc Surg 13:150-162, 1991.
11. Satiani B: A prospective randomized trial of aspirin in femoral popliteal and tibial bypass grafts. Angiology 36:608-616, 1985.
12. Tangelder MJD, Lawson JA, Algra A, et al: Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J Vasc Surg 30:701-709, 1999.
13. Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group: Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery: A randomised trial. Lancet 355:346-351, 2000.
14. Schweiger H, Klein P, Ruf S, et al: Avoiding early failure of tibial prosthetic bypass grafts. Thorac Cardiovasc Surg 2:148-150, 1987.
15. Wakefield TW, Lindblad B, Stanley TJ, et al: Heparin and protamine use in peripheral vascular surgery: A comparison between surgeons of the Society of Vascular Surgery and the European Society for Vascular Surgery. Eur J Vasc Surg 8:193-198, 1994.
16. Schweiger H, Klein P, Ruf S, et al: Avoiding early failure of tibial prosthetic bypass grafts. Thorac Cardiovasc Surg 2:148-150, 1987.
17. Samama CM, Gigou F, Ill P: Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: A multicenter open randomized study. Ann Vasc Surg 9(suppl):s45-s53, 1995.
18. Kretschmer G, Herbst F, Prager M, et al: A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 127:1112-1115, 1992.
19. Kretschmer G, Wenzl E, Wagner O, et al: Influence of anticoagulant treatment in preventing graft occlusion following saphenous vein bypass for femoro-popliteal occlusive disease. Br J Surg 73:689-692, 1986.
20. Kretschmer G, Wenzl E, Piza F, et al: The influence of anticoagulant treatment on the probability of function in femoropopliteal vein bypass surgery: Analysis of a clinical series (1970 to 1985) and interim evaluation of a controlled clinical trial. Surgery 102:453-459, 1987.
21. Arfvidsson B, Lundgren F, Drott C, et al: Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 159:556-560, 1990.
22. Clowes AW, Clowes MM: Kinetics of cellular proliferation after arterial injury. Heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res 58:839-845, 1986.
23. Clowes AW, Karnowsky MJ: Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265:625-626, 1977.
24. Wilson NV, Salisbury JR, Kakkar VV: The effect of low molecular weight heparin on intimal hyperplasia in vein grafts. Eur J Vasc Surg 8:60-64, 1994.
25. Hirsch J, Warkentin TE, Raschke R, et al: Heparin and low-molecular-weight heparin. Chest 114:s489-s510, 1998.
26. Bergan JJ: Deep venous thrombosis. In: Current Surgical Therapy, 6th Ed., ed. by Cameron JL. St Louis: Mosby, 1998, pp 885-903.
27. Bara L, Billaud E, Gramond G, et al: Comparative pharmacokinetics of a low molecular weight heparin (PK10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 39:631-636, 1985.
28. Warkentin TE, Levine MN, Hirsh J, et al: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin of unfractionated heparin. N Engl J Med 332:1330-1335, 1995.
29. Razuk A, Coimbra R, Karakhanian W, et al: Femoral neuropathy secondary to nontraumatic retroperitoneal hemorrhage following intravenous heparin therapy: A case report. J Vascular Surg 34:87-90, 2000.
30. Cohen M, Demers C, Gurfinkel EP, et al: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 337:447-452, 1997.
31. Levine M, Gent M, Hirsh J, et al: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334:677-681, 1996.
32. Lindblad B, Wakefield TW, Stanley TJ, et al: Pharmacological prophylaxis against postoperative graft occlusion after peripheral vascular surgery: A world-wide survey. Eur J Vasc Endovasc Surg 9:267-271, 1995.